High-risk bladder cancer: improving outcomes with perioperative chemotherapy
Despite treatment with radical cystectomy and pelvic lymph node dissection, muscle invasive bladder cancer has a relapse rate of 50%. Patients can develop regionally advanced or metastatic disease that ultimately leads to death. The addition of neoadjuvant or adjuvant chemotherapy to reduce the risk...
Main Authors: | Daniel Y.C. Heng, Jorge A. Garcia |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2011-12-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://oncologyreviews.org/index.php/or/article/view/103 |
Similar Items
-
High-risk bladder cancer: improving outcomes with perioperative chemotherapy
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01) -
Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
by: Nabil Ismaili, et al.
Published: (2011-09-01) -
Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer
by: DENG Kangli, et al.
Published: (2019-04-01) -
Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer
by: Jorge Esteban-Villarrubia, et al.
Published: (2023-01-01) -
Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
by: Serhat Sekmek, et al.
Published: (2023-11-01)